A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Haines
I
I
Elliott
P
P
Stanley
R
R
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use; D016265:Conflict of Interest; D003362:Cost-Benefit Analysis; D018592:Cross-Over Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D018572:Disease-Free Survival; D016527:Drug Costs; D017721:Hospital Costs; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000191:economics; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D002699:Chlorambucil; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine